Peripheral arterial disease and Virchow’s triad

Philip C. Bennett; Stanley H. Silverman; Paramjit S. Gill; Gregory Y. H. Lip

doi:10.1160/TH08-08-0518

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 101(06): 1032-1040
DOI: 10.1160/TH08-08-0518

Review Article

Schattauer GmbH

Peripheral arterial disease and Virchow’s triad

Philip C. Bennett

¹University Department of Medicine, City Hospital, Birmingham, UK

²Department of Vascular Surgery, City Hospital, Birmingham, UK

,

Stanley H. Silverman

²Department of Vascular Surgery, City Hospital, Birmingham, UK

,

Paramjit S. Gill

³Department of Primary Care and General Practice University of Birmingham, Edgbaston, Birmingham, UK

,

Gregory Y. H. Lip

¹University Department of Medicine, City Hospital, Birmingham, UK

› Institutsangaben

Abstract

Summary

Peripheral arterial disease (PAD) is an important global health-care problem associated with considerable morbidity and mortality. This disease is an important manifestation of atherosclerosis and the pathophysiological processes involved in its development, progression and complications are atherothrombosis and thromboembolism. Over 150 years ago, Virchow described a triad of abnormalities (abnormal blood flow, abnormal vessel wall and abnormal blood constituents) associated with thrombus formation (thrombogenesis). An improvement in biochemical techniques has allowed quantification of various components of Virchow’s triad, and as a consequence, there has been increasing interest in the measurement of such biomarkers in understanding the development and progression of PAD, as well as its symptomatic complications. This review discusses quantifiable components of Virchow’s triad that have been associated with PAD and their clinical utility as risk factors for PAD.

Keywords

Arterial thrombosis - clinical studies - risk factors

Volltext

Referenzen

References
1 Hirsch AT, Haskal ZJ. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic).. Circulation 2006; 113: e463-e465.
2 Norgren L. et al. on behalf of the TASC II working group. Inter-society consensus for the management of peripheral arterial disease (TASC II).. Eur J Vasc Endovasc Surg 2007; 33: S1-S75.
3 Criqui MH. et al. Mortality over a period of 10years in patients with peripheral arterial disease.. New Engl J Med 1992; 326: 381-386.
4 Criqui MH, Denenberg JO. The generalised nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease.. Vasc Med 1998; 3: 241-245.
5 Dormandy J. et al. Lower extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease.. Semin Vasc Surg 1999; 12: 118-122.
6 Virchow RLK. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin.. Frankfurt: Meidinger Sohn & Co.; 1856. In Virchow RLK, Thrombosis and Emboli (1846–1856).. Matzdorff AC, Bell WR. (transl). Canton: Science History Publications; 1998: 5-11 110.
7 Makin AJ. et al. Peripheral vascular disease and Virchow’s triad for thrombogenesis.. Q J Med 2002; 95: 199-210.
8 Chung I, Lip GYH. Virchow’s triad revisited: Blood constituents.. Pathophysiol Haemost Thromb 2003; 2004 33: 449-454.
9 Lowe GDO. Virchow’s triad revisited: Abnormal Flow.. Pathophysiol Haemost Thromb 2003; 2004 33: 455-457.
10 Lip GY, Blann AD. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new ‘vascular triad’.. Ann Med 2004; 36: 119-125.
11 Ross R. Atherosclerosis- An inflammatory disease.. New Engl J Med 1999; 340: 115-126.
12 Stary HC. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis.. Arterioscler Thromb Vasc Biol 1995; 15: 1512-1531.
13 Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and haemostasis.. Thromb Haemost 1997; 78: 53-59.
14 Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.. J Intern Med 2002; 251: 193-206.
15 Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.. Circ Res 2000; 87: 840-844.
16 Brevetti G. et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden.. J Vasc Surg 2003; 38: 374-379.
17 Anderson TJ. Assessment and treatment of endothelial dysfunction in humans.. J Am Coll Cardiol 1999; 34: 631-638.
18 Corretti MC. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilation of the brachial artery.. J Am Coll Cardiol 2002; 39: 257-265.
19 Bonetti PO. et al. Endothelial dysfunction: a marker of atherosclerotic risk.. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
20 Lip GY. Blann. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34: 255-265.
21 Zanetta L. et al. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumour angiogenesis.. Int J Cancer 2000; 85: 281-288.
22 Blann AD. et al. Von Willebrand factor, the endothelium and obesity.. Int J Obes Relat Metab Disord 1993; 17: 723-725.
23 Blann AD. et al. Von Willebrand factor and endothelial damage in essential hypertension.. J Hum Hypertens 1993; 7: 107-111.
24 Spencer CG. et al. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension; a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).. Hypertension 2002; 40: 61-66.
25 Ruggeri ZM. Perspectives series: cell adhesion in vascular biology. Von Willebrand Factor.. J Clin Invest 1997; 99: 559-564.
26 Blann AD. et al. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease.. Thromb Res 2000; 97: 209-216.
27 Seigneur M. et al. Circulating endothelial markers and ischaemic status in peripheral occlusive arterial disease.. Nouv Rev Fr Haematol 1995; 37: 171-173.
28 Lee AJ. et al. Determinants of fibrin d-dimer in the Edinburgh Artery Study.. Arterioscler Thromb Vasc Biol 1995; 15: 1094-1097.
29 Cassar K. et al. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease.. Eur J Endovasc Surg 2005; 29: 171-176.
30 Cassar K. et al. Platelet activation is increased in peripheral arterial disease.. J Vasc Surg 2003; 38: 99-103.
31 Woodburn KR. et al. Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia.. Eur J Vasc Endovasc Surg 1995; 10: 272-278.
32 Peterson J. et al. Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds.. Am J Pathol 1999; 155: 1569-1575.
33 Ishii H. et al. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells.. Thromb Haemost 1991; 65: 618-623.
34 Boffa MC. et al. Plasma thrombomodulin as a marker of endothelial damage.. Nouv Rev Fr Hematol 1991; 33: 529-530.
35 Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface.. FASEB J 1995; 9: 946-955.
36 Blann AD. et al. Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease.. Eur J Clin Invest 1997; 27: 916-921.
37 Constans J. et al. Endothelial function, platelet activation and coagulation in lower limb occlusive arterial disease during treadmill exercise: correlations with transcutaneous oxygen pressure.. Thromb Res 2000; 99: 557-561.
38 Taskiris DA. et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease.. Atherosclerosis 1999; 142: 193-200.
39 Salomaa V. et al. Cross-sectional association of soluble thrombomodulin with mild peripheral arterial disease: the ARIC study. Atherosclerosis Risk in Communities.. Atherosclerosis 2001; 157: 309-314.
40 Sernau T. et al. Thrombomodulin is a marker of microvascular, but not for macrovascular endothelial cell damage.. Vasa 1995; 24: 347-353.
41 Peter K. et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin.. Arterioscler Thromb Vasc Biol 1997; 17: 505-512.
42 Blann AD. et al. Circulating endothelial cells. Biomarker of vascular disease.. Thromb Haemost 2005; 93: 228-235.
43 Lee KW. et al. Inter-relationships of indices of endothelial damage/ dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes.. Int J Cardiol 2006; 111: 302-308.
44 Strijbos MH. et al. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage.. Thromb Haemost 2008; 100: 642-647.
45 Rajagopalan S. et al. Endothelial cell apoptosis in systemic lupus erythematosis: a common pathway for abnormal vascular function and thrombosis propensity.. Blood 2004; 103: 3677-3683.
46 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis.. Circ Res 2001; 88: 756-762.
47 Freedman JE. et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes.. Circulation 1998; 98: 1481-1486.
48 Makin AJ. et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells.. Eur Heart J 2004; 25: 371-376.
49 Makin AJ. et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis?. Clinical Science 2003; 104: 397-404.
50 Blann AD. et al. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls.. Atherosclerosis 2000; 152: 29-34.
51 Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease.. Clinica Chimica Acta 2006; 368: 33-47.
52 Davies MJ. et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-Selectin in human atherosclerosis.. J Path 1993; 171: 223-229.
53 Khalegi M. et al. Association of soluble cell adhesion molecules with ankle-brachial index in a biethnic cohort of predominantly hypertensive individuals.. Clin Chem 2008; 54: 1788-1795.
54 Iwashima Y. et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease.. Atherosclerosis 2006; 188: 384-390.
55 Pradhan AD. et al. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men.. Circulation 2002; 106: 820-825.
56 Tzoulaki I. et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study.. Eur Heart J 2007; 28: 354-362.
57 Silvestro A. et al. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification.. Thromb Haemost 2005; 93: 559-563.
58 Lee WL. et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patents with symptomatic advanced systemic arterial diseases.. Atherosclerosis 2004; 176: 125-132.
59 Allan PL. et al. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study.. Stroke 1997; 28: 348-353.
60 O’Leary DH. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.. N Engl J Med 1999; 340: 14-22.
61 Markus H. et al. Increased common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms.. Stroke 2001; 32: 2465-2471.
62 Mohan V. et al. Intimal medial thickness of the carotid artery in South Indian diabetic and non-diabetic subjects: the Chennai Urban Population Study (CUPS).. Diabetologia 2000; 43: 494-499.
63 Baldassarre D. et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis.. Ann Med 2008; 40: 21-44.
64 Baldassarre D. et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events.. Atherosclerosis 2007; 191: 403-408.
65 Bernard S. et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects.. Diabetes Care 2005; 28: 1158-1162.
66 McDermott MM. et al. Ankle-Brachial Index and subclinical cardiac and carotid disease. The Multi-Ethnic Study of Atherosclerosis.. Am J Epidemiol 2005; 162: 33-41.
67 Price JF. et al. Ankle brachial index and intima media thickness predict cardiovascular events similarly and increased prediction when combined.. J Clin Epidemiol 2007; 60: 1067-1075.
68 Laurent S. et al. on behalf of the European Network for Non-invasive investigation of larger arteries.. Eur Heart J 2006; 27: 2588-2605.
69 Chobnanian AV. Isolated systolic hypertension in the elderly.. N Eng J Med 2007; 357: 789-796.
70 Avolio AP. et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China.. Circulation 1985; 71: 202-210.
71 Laurent S. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.. Hypertension 2001; 37: 1236-1241.
72 Meaume S. et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age.. Arterioscler Thromb Vasc Biol 2001; 21: 2046-2050.
73 Kals J. et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis.. Am J Hypertens 2006; 19: 902-908.
74 Tai NR. et al. In vivo femoropopliteal arterial wall compliance in subjects with and without lower limb vascular disease.. J Vasc Surg 1999; 30: 936-945.
75 McVeigh GE. et al. Vascular abnormalities associated with long term cigarette smoking identified by arterial waveform analysis.. Am J Med 1997; 102: 227-231.
76 Seals DR. et al. Habitual exercise and arterial aging.. J Appl Physiol 2008; 105: 1323-1332.
77 Khaleghi M, Kullo IJ. Aortic augmentation index is associated with the ankle brachial pressure index: A community-based study.. Atherosclerosis 2007; 195: 248-253.
78 Brewer LC. et al. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease.. Atherosclerosis 2007; 191: 384-390.
79 Rajagopalan S. et al. Platelet activation increases with the severity of peripheral arterial disease: Implications for clinical management.. J Vasc Surg 2007; 46: 485-490.
80 Holme PA. et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis.. Arterioscler Thromb Vasc Biol 1997; 17: 646-653.
81 Kroll MH. et al. Platelets and shear stress.. Blood 1996; 88: 1525-1541.
82 Nomura S, Komiyama Y. Shear stress and platelet-derived microparticles.. Rinsho Byori 1997; 45: 927-933.
83 Cella G. et al. Beta thromboglobulin, platelet production time and platelet function in vascular disease.. Br J Haematol 1979; 43: 127-136.
84 Robless PA. et al. Increased platelet aggregation and activation in peripheral arterial disease.. Eur J Endovasc Surg 2003; 25: 16-22.
85 Kudoh T. et al. Relation between platelet micro-aggregates and ankle brachial index in patients with peripheral arterial disease.. Thromb Res 2006; 117: 263-269.
86 Ridker PM. et al. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peipheral arterial disease.. J Am Med Assoc 2001; 285: 2481-2485.
87 Koksch M. et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease.. Eur J Endovasc Surg 2001; 21: 147-154.
88 Tan KT. et al. Platelet microparticles and soluble P-selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers.. Ann Med 2005; 37: 61-66.
89 Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants.. Q J Med 2003; 96: 711-729.
90 Fibrinogen Studies Collaboration. et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality.. J Am Med Assoc 2005; 294: 1799-1809.
91 Blann AD, Lip GYH. Virchow’s Triad revisited: The importance of soluble coagulation factors, the endothelium, and platelets.. Thromb Res 2001; 101: 321-327.
92 Price JF. et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edinburgh Artery Study.. Eur Heart J 1999; 20: 344-353.
93 Wattanakit K. et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.. Atherosclerosis 2005; 180: 389-397.
94 Lip GYH. et al. Baseline abnormalities of endothelial function and thrombogenesis in relation to restenosis in essential hypertension.. Blood Coagul Fibrinolysis 2002; 13: 35-41.
95 Vene N, Mavri A, Kosmelj K. et al. High D-dimer-levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulation therapy.. Thromb Haemost 2003; 90: 1163-1172.
96 Schillinger M. et al. Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries.. Thromb Haemost 2002; 87: 959-965.
97 Roller RE. et al. Changes in the fibrinolytic system with peripheral arterial occlusive disease undergoing percutaneous transluminal angioplasty.. Thromb Res 1999; 94: 241-247.
98 Laxdal E. et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries.. Eur J Vasc Endovasc Surg 2006; 31: 244-250.
99 Bartlett JW. et al. Assessing the contribution of fibrinogen in predicting risk of death in mean with paripheral arterial disease.. J Thromb Haemost 2009; 7: 270-276.
100 Matsuo T. et al. Fibrin D-dimer in thrombogenic disorders.. Semin Thromb Haemost 2000; 26: 101-107.
101 McDermott MM. et al. D-dimer, inflammatory markers and lower extremioty functioning in patients with and without peripheral arterial disease.. Circulation 2003; 107: 3191-3198.
102 Danesh J. et al. Fibrin D-dimer and Coronary heart Disease: A prospective study and Meta-analysis.. Circulation 2001; 103: 2323-2327.
103 Lassila R. et al. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin.. Arterioscler Thromb 1993; 13: 1738-1742.
104 Musicant SE. et al. Prospective evaluation of the relationship between C-reactive protein, d-dimer and progression of peripheral arterial disease.. J Vasc Surg 2006; 43: 772-780.
105 Mota AP. et al. Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index.. Angiology Nov. 2008 prepub online.
106 Ridker PM. et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.. Circulation 1994; 90: 2236-2240.
107 Reiner AP. et al. Haemostatic risk factors and arterial thrombotic disease.. Thromb Haemost 2001; 85: 584-595.
108 Philipp CS. et al. Association of haemostatic factors with peripheral vascular disease.. Am Heart J 1997; 134: 978-984.
109 Sobel BE. Increased PAI-1 and vasculopathy: a reconsilable paradox.. Circulation 1999; 99: 2496-2498.
110 Loskutoff DJ. et al. Regulation of PAI-1 gene expression in vivo.. Thromb Haemost 1993; 70: 135-137.
111 Felmelden DC, Lip GYH. Endothelial function and its assessment.. Expert Opin Investig Drugs 2005; 14: 1319-1336.
112 Cessari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischaemic cardiomyopathy.. Arterioscler Thromb Vasc Biol 1999; 19: 1378-1386.
113 Devaraj S. et al. C-Reactive protein increases Plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis.. Circulation 2003; 107: 398-404.
114 Sawa H. et al. Increased intramural expression of Plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis.. J Am Coll Cardiol 1994; 24: 1742-1748.
115 Kronenberg F. et al. Role of Lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck Study.. Circulation 1999; 100: 1154-1160.
116 Loscalzo J. et al. Lipoprotein(a), fibrin binding, and plasminogen activation.. Arteriosclerosis 1990; 10: 240-245.
117 Paraskevas KI. et al. The role of fibrinogen and fibrinolysis in peripheral arterial disease.. Throb Res 2008; 122: 1-12.
118 Palabrica TM. et al. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue Plasminogen activator-mediated thrombolysis.. Nat Med 1995; 1: 256-259.
119 Cheng SW. et al. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.. Eur J Vasc Endovasc Surg 1997; 14: 17-23.
120 Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan.. Diabetes Care 2004; 27: 517-521.
121 Libby P. et al. Inflammation and atherosclerosis.. Circulation 2002; 105: 1135-1143.
122 American Diabetes Association.. Peripheral arterial disease in people with diabetes.. Diabetes Care 2003; 26: 3333-3341.
123 Vinik AI. et al. Platelet dysfunction in type 2 diabetes.. Diabetes Care 2001; 24: 1476-1485.
124 Tzoulaki I. et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.. Circulation 2005; 112: 976-983.
125 Allison MA. et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA).. J Am Coll Cardiol 2006; 48: 1190-1197.
126 Armitage JD. et al. The role of endothelial cell reactive antibodies in peripheral arterial disease.. Eur J Endovasc Surg 2006; 31: 170-175.
127 Riba R. et al. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels.. Atherosclerosis 2004; 175: 69-75.
128 Hogh AL. et al. C-reactive protein predicts future arterial and cardiovascular events in patients with symptomatic peripheral arterial disease.. Vasc Endovascular Surg 2008; 42: 341-347.
129 Wall RT. et al. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury.. Thromb Res 1980; 18: 113-121.
130 Silverman MD. et al. Homocysteine unregulates vascular cell adhesion molecule-1 expression in cultures aortic endothelial cells and enhances monocyte adhesion.. Arterioscler Thromb Vasc Biol 2002; 22: 587-592.
131 Moghadasian MH. et al. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background.. Arch Intern Med 1997; 157: 2299-2308.
132 Welch GN, Loscolzo J. Homocysteine and atherosthrombosis.. N Eng J Med 1998; 338: 1042-1045.
133 Boushey CJ. et al. A quatitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.. J Am Med Assoc 1995; 274: 1049-1057.
134 Taylor Jr LM. Elevated plasma homocysteine as a risk factor for peripheral arterial disease: what is the evidence?. Semin Vasc Surg 2003; 16: 215-222.
135 Heneghan HM, Sultan S. Homocysteine, the cholesterol of the 21^st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for crtitical limb ischaemia.. J Endovasc Ther 2008; 15: 399-407.
136 Lowe GDO. et al. Blood viscosity, fibrinogen, and activation of coagulation and leokocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study.. Circulation 1993; 87: 1915-1920.
137 Lee AJ. et al. Blood viscosity and elevated carotid intima-media thickness in men and women: The Edinburgh Artery Study.. Circulation 1998; 97: 1467-1473.
138 Smith FB. et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants.. Br J Haematol 1998; 100: 758-763.
139 Van Der Loo B. et al. Carotid intima-media thickness, carotid wall shear stress and restenosis after femoro-popliteal percutaneous transluminal angioplasty (PTA).. Eur J Vasc Surg 2005; 30: 469-474.
140 Gori T. et al. Endothelium and haemorheology.. Ann Ist Sanita 2007; 43: 124-129.
141 Shaaban AM, Duerinckx AJ. Wall shear stress and early atherosclerosis: A review.. AJR 2000; 174: 1657-1665.
142 Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis.. Lab Invest 2005; 85: 9-23.
143 Niwa K. et al. The effects of a shear flow on the up-take of LDL and acetylated LDL by an EC monoculture and an EC-SMC coculture.. Ann Biomed Eng 2004; 32: 537-543.
144 Chiu JJ. et al. Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumour necrosis factor-alpha in endothelial cells.. Arteriosclerosis Thrombosis Vasc Biol 2004; 24: 73-79.
145 Walpola PL. et al. Expression on ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress.. Arteriosclerosis Thrombosis Vasc Biol 1995; 15: 2-10.
146 Spring S. et al. Decreased wall shear stress in the common carotid artery of patients with peripheral arterial disease or abdominal aortic aneurysm: Relation to blood rheology, vascular risk factors, and intimamedial thickness.. J Vasc Surg 2006; 43: 56-63.
147 Irace C. et al. Wall shear stress is associated with intima-media thickness and carotid atherosclerosis in subjects at low coronary heart disease risk.. Stroke 2004; 35: 464-468.
148 Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries.. Circ Res 1990; 66: 1045-1066.
149 Gnasso A. et al. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis.. Stroke 1997; 28: 993-998.
150 Zarins CK. et al. Carotid bifurcation atherosclerosis; quantitative correlation of plaque localisation with flow velocity profiles and wall shear stress.. Circ Res 1983; 53: 502-514.
151 Khaleghi M. et al. Haemostatic markers are associated with measures of vascular disease in adults with hypertension.. J Hum Hypertens 2009; 1: 1-8.
152 Gosk-Bierska I. et al. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischaemia: preliminary study.. Int Angiol 2008; 27: 296-301.
153 McDermott MM. et al. Circulating blood markers and functional impairment in peripheral arterial disease.. J Am Geriatr Soc 2008; 56: 1504-1510.
154 Vidula H. et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study.. Ann Intern Med 2008; 148: 85-93.
155 Sodhi HS. et al. Prevalence of peripheral arterial disease by ankle-brachial index and its correlation with carotid intimal thickness and coronary risk factors in Nepalese population over the age of forty years.. Kathmandu Univ Med. J 2007; 1: 12-15.
156 Cleanthis M. et al. Platelet monocyte aggregates and monocyte chemoattractant protein-1 are not limited by aspirin in critical limb ischaemia.. Eur J Endovasc Surg 2007; 33: 725-730.
157 Brevetti G. et al. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity.. J Vasc Surg. 2006; 44: 101-107.
158 Unlu Y. et al. Comparison of levels of inflammatory markers and haemostatic factors in the patients with and without peripheral arterial disease.. Thromb Res 2006; 117: 357-364.
159 Sofi F. et al. Thrombophilic risk factors for symptomatic peripheral arterial disease.. J Vasc Surg 2005; 41: 255-260.
160 Wildman RP. et al. Relation of inflammation to peripheral arterial disease in the National Health and Nutrition Examination Survey, 1999–2002.. Am J Cardiol 2005; 96: 1579-1583.
161 Urge J. et al. Pharmacotherapeutical approaches to decreasing haematocrit and increasing claudication distance in diabetic patients with peripheral vascular disease.. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 267-270.
162 Parsson H. et al. Activation of coagulation and fibrinolytic systems with CLI is not normalised after surgical revascularisation.. Eur J Endovasc Surg 2004; 27: 186-192.
163 Koscielny J. et al. Blood fluidity, fibrinogen, and cardiovascular risk factors of occlusive arterial disease: Results of the Aachen study.. Clin Haemorheol Micro-circ 2004; 31: 185-195.

Zusatzmaterial

Zusatzmaterial